HD5-Derived Peptide Inhibits HCMV Viral Entry
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for treating Herpesviridae infections, particularly those caused by Cytomegalovirus (HCMV), are associated with significant side effects and lack effective solutions for pregnant women and newborns, with existing treatments primarily inhibiting viral replication rather than preventing initial cell infection.
Innovation Solution
A peptide with a specific sequence, derived from human defensin 5, that inhibits HCMV infection by preventing viral entry into cells, offering antiviral effects without toxicity and efficacy against resistant strains, comprising nonpolar and polar amino acids, cysteine, and arginine residues, potentially used in combination with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents (Ganciclovir, Foscarnet, Cidofovir, Letermovir) are used to inhibit viral replication, then viral replication is inhibited, but major side effects such as myelo- and nephro-toxicity occur
Solution Approach 1:
The patent replaces the chemical mechanism of nucleoside analogues and DNA polymerase inhibitors with a peptide-based mechanism. The peptide HD5 (1-9) acts as a viral entry inhibitor by directly interfering with the virus-cell interaction process, substituting the traditional intracellular replication inhibition approach with an extracellular entry block mechanism, thereby avoiding the toxic side effects associated with current replication inhibitors
Solution Approach 2:
The patent changes the therapeutic mechanism from molecular-level replication inhibition to peptide-based entry prevention. By modifying the approach from acting on viral DNA replication enzymes to acting on the viral envelope and cell membrane interaction, the patent achieves viral inhibition without the harmful metabolic side effects of current agents
2Reliability
If Ganciclovir is used to treat HCMV infection, then viral replication is inhibited, but the agent lacks activity against resistant strains and causes significant toxicity
Solution Approach 1:
The patent substitutes the DNA polymerase inhibition mechanism with a viral entry inhibition mechanism. The peptide HD5 (1-9) binds to the viral envelope or cell membrane components, preventing virus entry into cells before replication can occur. This mechanism is not affected by UL97 gene mutations that confer Ganciclovir resistance, as it acts upstream of the replication process
Solution Approach 2:
The patent applies preliminary action by blocking viral entry before replication can begin. The peptide prevents the virus from entering the cell in the first place, rather than allowing entry and then inhibiting replication. This preliminary blockage at the entry stage makes the treatment effective against resistant strains that can replicate despite Ganciclovir presence
3Reliability
If existing therapeutic agents are used, then viral replication is inhibited, but there is no evidence-based therapeutic approach for pregnant women and newborns
Solution Approach 1:
The patent replaces harmful chemical replication inhibitors with a peptide-based entry inhibitor that has a different mechanism of action. The peptide HD5 (1-9) acts on the viral envelope and cell membrane interaction, which is a physical-biological process that can be safely applied across different age groups and physiological states, including pregnancy and neonatal periods
Solution Approach 2:
The patent changes the therapeutic approach from replication inhibition to entry prevention, creating a treatment paradigm that is safe for use in pregnant women and newborns. The peptide mechanism does not interfere with fetal development or maternal physiology in the way that nucleoside analogues and DNA polymerase inhibitors do
Data Source
Figure 1A~1B
Figure 2A~2D
Figure 3A~3B
AI summary
The present invention relates to new peptides the amino acid sequences of which are derived from HD-5, for use in the treatment and/or prevention of Herpesviridae infections, in particular for treating and/or preventing a Betaherpesviridae infection, such as a HCMV-infection.